- Home
- WNS vs BLTE Comparison
WNS vs BLTE Comparison
Compare WNS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNS
- BLTE
- Stock Information
- Founded
- WNS 1996
- BLTE 2018
- Country
- WNS India
- BLTE United States
- Employees
- WNS N/A
- BLTE N/A
- Industry
- WNS Business Services
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- WNS Consumer Discretionary
- BLTE Health Care
- Exchange
- WNS Nasdaq
- BLTE Nasdaq
- Market Cap
- WNS 2.3B
- BLTE 2.1B
- IPO Year
- WNS N/A
- BLTE 2022
- Fundamental
- Price
- WNS $46.58
- BLTE $56.21
- Analyst Decision
- WNS Buy
- BLTE Strong Buy
- Analyst Count
- WNS 7
- BLTE 4
- Target Price
- WNS $60.43
- BLTE $89.00
- AVG Volume (30 Days)
- WNS 432.0K
- BLTE 43.9K
- Earning Date
- WNS 01-23-2025
- BLTE 03-10-2025
- Dividend Yield
- WNS N/A
- BLTE N/A
- EPS Growth
- WNS N/A
- BLTE N/A
- EPS
- WNS 2.50
- BLTE N/A
- Revenue
- WNS $1,308,696,000.00
- BLTE N/A
- Revenue This Year
- WNS N/A
- BLTE N/A
- Revenue Next Year
- WNS $7.73
- BLTE N/A
- P/E Ratio
- WNS $18.64
- BLTE N/A
- Revenue Growth
- WNS 2.07
- BLTE N/A
- 52 Week Low
- WNS $39.85
- BLTE $31.01
- 52 Week High
- WNS $72.57
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- WNS 49.08
- BLTE 39.68
- Support Level
- WNS $44.59
- BLTE $52.03
- Resistance Level
- WNS $48.12
- BLTE $57.10
- Average True Range (ATR)
- WNS 1.40
- BLTE 3.14
- MACD
- WNS 0.14
- BLTE -0.34
- Stochastic Oscillator
- WNS 70.78
- BLTE 25.85
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.